Effect of Brown Rice on the Risk Factors for Metabolic Syndrome
Biological Functions of Brown Rice on Metabolic Syndrome: A Randomized Cross-over Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Clinical and Translation Research Center, Tufts Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men & postmenopausal women, aged >50 years
- BMI >30 kg/m2 and/or waist/hip ratio >0.9 for men, >0.85 for women
- plus any two of the following four MetS factors
- Fasting plasma TG: 150-400 mg/dL (1.7 - 4.52 mmol/L)
- Fasting plasma HDL cholesterol: <40 mg /dL (1.03 mmol/L) for men, <50 mg/dL (1.29 mmol/L) for women
- Blood pressure: SBP, 130-160 mmHg and/or DBP 85-95 mmHg
- Fasting plasma glucose: fasting blood glucose 100-125 mg/dL (5.55- 6.94 mmol/L) and no medication for blood glucose regulation and no use of insulin
Exclusion Criteria:
- Cigarette smoking and/or nicotine replacement use
- Individuals taking estrogen
- Use of blood glucose lowering medications or insulin
- Regular use (>2x/wk) of any stomach acid-lowering medications or laxatives
- Regular use (>2x/wk) of medication for inflammation
- Regular use of medication for hypercoagulation
- Cardiovascular (heart) disease
- Gastrointestinal disease
- Renal or chronic kidney disease
- Endocrine disease: including diabetes, untreated thyroid disease
- Rheumatoid arthritis
- Active treatment for any type of cancer, except basal cell carcinoma, within 1 year prior to study admission
- Systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg
- Regular use of oral steroids except topical OTC steroids
- Regular daily intake of ≥2 alcoholic drinks
- Infrequent (<3/wk) or excessive (>3/d) number of regular bowel movements
- Illicit drug use
- Vegetarians
- No fish oil supplements (including cod liver oil) for one month prior to study admission
- No dietary supplements, including those containing any vitamins, minerals, herbs, plant concentrates (including garlic, gingko, St. John's wort) or homeopathic remedies, for one month prior to study admission
- On or planning a weight reducing regimen using a dietary approach of dietary supplements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Brown Rice
Eat 100g of brown rice cake (3 packets) per day for 5 weeks
|
brown rice cake
|
|
Experimental: White Rice
Eat 100g of white rice cake (3 packets) per day for 5 weeks
|
white rice cake
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Glucoregulation (glucose, insulin and HbA1c)
Time Frame: Change from baseline after 5 week intervention phase
|
Change from baseline after 5 week intervention phase
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Inflammatory markers (high sensitivity CRP, soluble intercellular adhesion molecule 1, serum amyloid A, vascular cell adhesion molecule 1)
Time Frame: Change from baseline after 5 week intervention phase
|
Change from baseline after 5 week intervention phase
|
|
Lipid profile (Total cholesterol, HDL and Triglycerides)
Time Frame: Change from baseline after 5 week intervention phase
|
Change from baseline after 5 week intervention phase
|
|
Oxidative stress markers - total antioxidant potential (TAP), total thiols, tocols, Ferric Reducing Antioxidant Power (FRAP), malondialdehyde (MDA), uric acid
Time Frame: Change from baseline after 5 week intervention phase
|
Change from baseline after 5 week intervention phase
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Oliver Chen, Ph.D., Tufts University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11066
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.